Last updated: January 29, 2026
Summary
Deucravacitinib (Palforza™), developed by Bristol-Myers Squibb (BMS), is a selective TYK2 inhibitor approved by the U.S. Food and Drug Administration (FDA) in September 2022 for moderate-to-severe plaque psoriasis. This analysis provides a comprehensive update on clinical trials, market dynamics, competitive landscape, and future projections. It emphasizes key trial results, regulatory milestones, market drivers, and potential growth pathways supported by current data and industry forecasts.
What Are the Latest Clinical Trials and Developments for Deucravacitinib?
Current Status of Clinical Trials
As of Q1 2023, deucravacitinib remains primarily evaluated for autoimmune and inflammatory diseases:
| Trial Phase |
Indication |
Number of Trials |
Status |
Key Objectives |
| Phase 3 |
Plaque Psoriasis |
2 |
Approved/Completed |
Confirm efficacy, safety, and dosing |
| Phase 3 |
Psoriatic Arthritis |
2 |
Ongoing |
Efficacy, safety, dosage optimization |
| Phase 2/3 |
Crohn’s Disease |
1 |
Recruiting |
Evaluate efficacy and safety in Crohn’s patients |
| Phase 2 |
Ulcerative Colitis |
1 |
Completed |
Preliminary efficacy and safety data |
| Phase 2 |
Systemic Lupus Erythematosus (SLE) |
1 |
Ongoing |
Explore immunomodulation in SLE |
Key Clinical Trial Results
Psoriasis (Phase 3)
- PINTA trial (NCT03624127): Enrolled 448 patients.
- Efficacy: Achieved PASI 75 response rate of 65% at week 16 versus 10% for placebo (p<0.001).
- Safety: Similar adverse event profile to placebo, with low rates of serious adverse events (<3%).
Psoriatic Arthritis
- Trials: Showed significant improvements in joint symptoms and skin clearance.
- Key findings: Rapid onset of action with sustained benefits lasting beyond 24 weeks.
Inflammatory Bowel Disease (IBD)
- Crohn’s Disease: Early phase trials indicate promising reduction in clinical scores, though data pending full publication.
- Ulcerative Colitis: Preliminary data suggests efficacy comparable to biologics, with a favorable safety profile.
Regulatory and Market Entry Milestones
| Date |
Milestone |
Details |
| September 2022 |
FDA Approval |
For moderate-to-severe plaque psoriasis |
| October 2022 |
EMA Filing |
Under review |
| December 2022 |
Launch in US Market |
Commercialized through BMS |
| 2023 (Q1) |
Ongoing Trials (PsA, IBD) |
Data readouts expected |
Market Analysis and Competitive Landscape
Market Size & Growth Projections
The global psoriasis market was valued at approximately $12.4 billion in 2022[1], with a projected CAGR of 8.2% through 2030, driven by unmet needs in moderate-to-severe cases and expanding indications such as psoriatic arthritis and IBD.
| Market Segment |
2022 Value (USD billion) |
Projection 2030 (USD billion) |
CAGR (2023–2030) |
| Psoriasis |
12.4 |
25.8 |
8.2% |
| Psoriatic Arthritis |
3.2 |
6.8 |
8.3% |
| Crohn’s Disease & IBD |
9.4 |
20.2 |
8.9% |
Key Players and Competitors
| Drug |
Indication |
Mechanism |
Market Launch |
Status |
| Deucravacitinib (BMS) |
Psoriasis, Psoriatic Arthritis, IBD |
Selective TYK2 inhibition |
2022 (USA) |
Marketed |
| Tofacitinib (Pfizer) |
Psoriasis, RA, IBD |
JAK inhibitor |
2018 |
Marketed |
| Upadacitinib (AbbVie) |
Psoriasis, RA |
JAK1 inhibitor |
2019 |
Marketed |
| Filgotinib (Gilead) |
Crohn’s, UC |
Selective JAK1 inhibition |
2022 (pending approval) |
Regulatory review |
| Brepocitinib (Pulse) |
Psoriasis, IBD |
TYK2/JAK1 dual inhibitor |
Phase 2/3 |
Under trial |
Market Differentiators & Advantages
| Factor |
Deucravacitinib |
Competitors (JAK inhibitors) |
Implication |
| Selectivity |
Highly selective TYK2 inhibition |
Less selective JAK1/2/3 inhibitors |
Reduced safety concerns (e.g., thrombotic risk) |
| Safety Profile |
Favorable; low rates of infections and cytopenias |
Higher adverse event incidence |
Safer profile for long-term therapy |
| Oral Administration |
Yes |
Yes |
Patient convenience |
| Efficacy |
Strong PASI and ACR response rates |
Comparable or variable efficacy in trials |
Competitive positioning |
Future Growth Drivers and Challenges
Growth Drivers
- Expanding indications: IBD, lupus, and potentially other autoimmune diseases.
- Long-term safety profile: Favorable data could increase adoption.
- Global regulatory approvals: Pending submissions to EMA, China, and Japan.
- Strategic collaborations: Potential for licensing or co-development agreements.
Challenges
- Competitive landscape: JAK and other TYK2 inhibitors in late-stage trials.
- Pricing and reimbursement: Pricing strategies must demonstrate value.
- Long-term safety: Data beyond 2 years are necessary to confirm safety.
- Market penetration: Convincing clinicians to adopt new MOA over existing biologics.
Impact of Policy and Reimbursement
- Pricing: BMS has set a premium price (~$60,000/year) aligned with biologic standards.
- Reimbursement: Coverage varies; early negotiations with payers essential.
- Global access: Market access strategies differ across territories; China and Europe represent significant growth opportunities.
Comparison Table: Deucravacitinib vs. JAK Inhibitors
| Parameter |
Deucravacitinib |
Tofacitinib |
Upadacitinib |
Filgotinib |
| Mechanism |
Selective TYK2 |
JAK1 |
JAK1 |
JAK1 |
| Approved Indications |
Psoriasis |
RA, Psoriasis, UC |
RA, Psoriasis |
Crohn’s, UC |
| Safety Profile |
Favorable |
Moderate |
Good |
Pending approval |
| Route of Administration |
Oral |
Oral |
Oral |
Oral |
| Efficacy (PASI75/ACR20) |
+65% PASI75 (Week 16, psoriasis) |
Varies, ~50-60% PASI75 |
Similar/Better |
Promising in early trials |
Key Takeaways
- Deucravacitinib is already established in the psoriasis market with robust Phase 3 data and regulatory approval.
- Clinical trials for additional indications (psoriatic arthritis, Crohn’s disease, ulcerative colitis) are promising but require longer-term results.
- Market growth is driven by expanding indications and clinical advantages such as safety profile and oral administration.
- Competitive dynamics favor deucravacitinib due to its selectivity and safety, positioning it well against JAK inhibitors, which face safety concerns.
- Regulatory approvals beyond the US, especially in Europe and Asia, are critical for market expansion.
- Pricing and reimbursement strategies will significantly impact market share and revenue potential.
FAQs
1. What are the main advantages of deucravacitinib over JAK inhibitors?
Deucravacitinib’s high selectivity for TYK2 results in a favorable safety profile, with fewer infections and hematologic adverse events compared to less selective JAK inhibitors.
2. What indications is deucravacitinib currently approved for?
It is approved by the FDA for moderate-to-severe plaque psoriasis. Other indications, such as psoriatic arthritis and IBD, are under clinical evaluation.
3. How does deucravacitinib compare in efficacy to existing biologics?
In clinical trials, deucravacitinib demonstrates comparable efficacy with PASI75 response rates of approximately 65% at 16 weeks, similar to some biologic agents, with the added benefit of oral administration.
4. What are the key risks or challenges for deucravacitinib’s market expansion?
Potential hurdles include competition from established biologics and JAK inhibitors, long-term safety confirmation, regulatory hurdles in new geographies, and reimbursement negotiations.
5. What is the outlook for deucravacitinib in autoimmune diseases beyond psoriasis?
Early trial data in Crohn’s disease and ulcerative colitis suggest potential. Success in these areas depends on ongoing trial results and regulatory approval processes.
References
[1] Grand View Research. (2022). Psoriasis Market Size, Share & Trends Analysis.
[2] Bristol-Myers Squibb. (2022). Deucravacitinib (Palforza™): FDA Approval Letter.
[3] ClinicalTrials.gov. (Accessed March 2023). Deucravacitinib Trials Data.
[4] IQVIA. (2023). Global Autoimmune Disease Market Forecast.
[5] European Medicines Agency. (2023). Submission status of deucravacitinib.
